Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Group-A and group-C meningococcus polysaccharide-adsorption diphtheria tetanus combined vaccine and production process thereof

A meningococcal and tetanus vaccine technology, applied in the directions of microorganisms, antibacterial drugs, bacterial antigen components, etc., can solve the problem of single role of the vaccine, and achieve the effect of reducing the probability of disease, good preventive effect and reducing rejection reaction.

Inactive Publication Date: 2019-03-26
LIAONING MAOKANGYUAN BIO TECH CO LTD +1
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In recent decades, according to the immunization plan, the country has injected meningitis vaccine, diphtheria and tetanus vaccines to children free of charge. However, these vaccines have a single effect. The role of diphtheria and tetanus, and children aged 5-6 are the high-incidence group of these four epidemics, and they need to strengthen immune protection. Group A and group C meningococcal polysaccharide-adsorbed diphtheria-tetanus combined vaccine only needs one injection for the above situations , can prevent 4 kinds of epidemic diseases for children aged 5-6 at the same time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Group-A and group-C meningococcus polysaccharide-adsorption diphtheria tetanus combined vaccine and production process thereof
  • Group-A and group-C meningococcus polysaccharide-adsorption diphtheria tetanus combined vaccine and production process thereof
  • Group-A and group-C meningococcus polysaccharide-adsorption diphtheria tetanus combined vaccine and production process thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0047] Specific embodiments of the present invention will be described in detail below.

[0048] A group A group C meningococcal polysaccharide-adsorbed diphtheria-tetanus combined vaccine, comprising: adsorbed diphtheria-tetanus vaccine and group A group C meningitis polysaccharide vaccine, the adsorbed diphtheria-tetanus vaccine and group A group C meningitis polysaccharide vaccine Packed in two reagent bottles,

[0049] Wherein, every 1ml of the adsorbed diphtheria and tetanus vaccine contains less than 20Lf of diphtheria toxoid, less than 3Lf of tetanus toxoid, less than 3mg of aluminum hydroxide, and less than 7.5mg-9mg of sodium chloride;

[0050] Each 0.5 ml human dose of the group A and C meningitis polysaccharide vaccine contains 50 micrograms of group A meningococcal polysaccharide, 50 micrograms of group C meningococcal polysaccharide and 8 mg of lactose.

[0051] Further, the pH value of the adsorbed diphtheria and tetanus vaccine added to the group A group C meni...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a group-A and group-C meningococcus polysaccharide-adsorption diphtheria tetanus combined vaccine and a production process thereof. The combined vaccine contains an adsorption diphtheria tetanus vaccine and a group-A and group-C meningococcus polysaccharide vaccine which are respectively contained in two reagent bottles, wherein the content of diphtheria toxoid in each 1ml of the adsorption diphtheria tetanus vaccine is below 20Lf, the content of tetanus toxoid is below 3Lf, the content of aluminum hydroxide is below 3mg, and the content of sodium chloride is 7.5mg-9mg;and each human dose, namely 0.5ml of the group-A and group-C meningococcus polysaccharide vaccine contains 50 micrograms of group-A meningococcus polysaccharide, 50 micrograms of group-C meningococcuspolysaccharide vaccine and 8mg of lactose. The combined process is mainly used for preventing multiple high-incidence diseases of children of 5 and 6 years old through one injection. The invention further provides the production process of the group-A and group-C meningococcus polysaccharide-adsorption diphtheria tetanus combined vaccine.

Description

technical field [0001] The invention belongs to the technical field of vaccine production, and in particular relates to a group A group C meningococcal polysaccharide-adsorbed diphtheria-tetanus combined vaccine and a production process. Background technique [0002] Meningococcal meningitis is an acute respiratory infectious disease caused by Neisseria meningitides (Nm). The incidence of meningococcal disease is very high, and there have been several periodic pandemics, which have claimed the lives of tens of thousands of people and caused huge losses. In recent years, epidemic meningitis has repeatedly caused outbreaks and epidemics among primary and middle school students in my country. It has brought a huge threat to the health of the majority of primary and middle school students. [0003] Diphtheria (diphtheria) is an acute respiratory infectious disease caused by diphtheria bacillus, characterized by fever, shortness of breath, hoarseness, barking cough, white pseudome...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/095A61K39/05A61K39/08A61K39/116A61P31/04C12P19/04C08B37/00C12R1/01
Inventor 魏文进刘宗豪高辉李凤凯
Owner LIAONING MAOKANGYUAN BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products